Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brinzolamide/timolol

Drug Profile

Brinzolamide/timolol

Alternative Names: Azarga; Elazop; Timolol/brinzolamide

Latest Information Update: 15 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alcon
  • Developer Novartis
  • Class Amino alcohols; Antiglaucomas; Morpholines; Propanolamines; Sulfonamides; Thiadiazoles; Thiazines
  • Mechanism of Action Beta-adrenergic receptor antagonists; Carbonic anhydrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension

Most Recent Events

  • 09 Apr 2019 Novartis completed the spin-off of Alcon eye care devices business
  • 06 Sep 2016 No recent reports on development identified - Phase-III for Glaucoma and Ocular hypertension in USA (Ophthalmic)
  • 17 Apr 2013 Launched for Glaucoma in Malaysia, Singapore, Thailand, Taiwan and South Korea (Ophthalmic) prior to April 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top